The present study is the first costeffectiveness
analysis to examine the potential total direct medical
costs, mortality rate and QALYs gained by a program of daily
topical mupirocin application for preventing catheter-related infections
in incident PD patients. Our findings show that mupirocin
is a cost-effective option over a wide range of infection prevalence.